The Blues boss saw the World Cup winner put in another impressive performance against Newcastle, with the Frenchman thriving after shaking off knocks
Frank Lampard claims to have “so much faith” in N’Golo Kante after seeing the Chelsea midfielder face questions of his form, fitness and future.
The France international has two Premier League titles and a World Cup winners’ medal to his name, but has seen a move away from Stamford Bridge mooted.
Speculation was first sparked when Maurizio Sarri took to shifting the 29-year-old out of his favoured holding role.
Lampard has also used Kante in a more advanced position during his reign in west London, but has seen him shine of late in the berth that made him a household name.
Goal 50 Revealed: The best 50 players in the world
Another eye-catching showing sweeping up in front of the Blues’ back four was put in against Newcastle on Saturday, in a 2-0 win for Chelsea, with confidence restored to all concerned.
Lampard told reporters on the influence Kante can have when performing at the peak of his powers: “I know what you mean by quietly influential but he’s much more than that for us.
“Last year he missed 50 per cent of the games with injuries, he had a tough time for different reasons and we are working very hard on that to get him fit and fresh.
“Now we are managing his training and game time, but his levels of performances are really high.
“I keep saying every time I get asked about N’Golo that I have so much faith in him and the top midfield player that he is in world football.
“Not just breaking up and winning balls back, as we know that is a huge quality of his, but his passing and supporting in midfield and playing in that deeper role now has been a very comfortable transition for him. Really, really happy with him.”
Lampard added when asked if he considers Kante to be over the injury issues that have been holding him back: “I don’t want to tempt fate as at the minute he is going well. It’s a constant one for us where we are managing it.
“When I came in at the start of last season he had been injured from the Europa League final and that just rolled on through the year so we just chased it down from there. That was unfortunate and so unfortunate for us to lose him for 50 per cent of the games because of the level of player he is.
“We have had a better period of him to get him in a place where we are really happy with.
“We’re aware and we keep check on his training and numbers and how much distance he travels because every time you train and allow him off the leash in training he makes ridiculous output because of the way he plays.
“We are very careful with that and at the
European Commission approves Roche’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Tecentriq in combination with Avastin is the first and only cancer immunotherapy regimen approved in Europe for the treatment of unresectable hepatocellular carcinoma (HCC), the most common form of liver cancer
Tecentriq combination improved overall survival and progression-free survival compared with the previous standard of care
Basel, 2 November 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.
“Tecentriq in combination with Avastin is the first treatment to be approved in over a decade that has improved overall survival for people with previously untreated advanced or unresectable hepatocellular carcinoma,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “We’re delighted that people in Europe can now benefit from this combination and we look forward to working with individual countries within the EU to ensure people can access the combination as soon as possible.”
“The results of the IMbrave150 study mark a breakthrough in the treatment of advanced liver cancer, one of the few cancers with a rising death rate and limited options in the first-line setting,” said Dr Arndt Vogel, Professor of Medicine at Hannover Medical School. “After many failures in the last 12 years, the combination of Tecentriq and Avastin shows improvement in overall survival compared to sorafenib and offers patients the opportunity for improved disease control with a high overall response rate.”
The approval is based on results from the Phase III IMbrave150 study, which showed that Tecentriq in combination with Avastin reduced the risk of death (overall survival [OS]) by 42% (hazard ratio [HR]=0.58; 95% CI: 0.42–0.79; p=0.0006) and reduced the risk of disease worsening or death (progression-free survival [PFS]) by 41% (HR=0.59; 95% CI: 0.47–0.76; p<0.0001), compared with sorafenib. IMbrave150 is the first Phase III cancer immunotherapy study to show an improvement in both OS and PFS in people with unresectable HCC compared with sorafenib. Grade 3–4 adverse events occurred in 57% of people receiving Tecentriq and Avastin and 55% of people receiving sorafenib. The most frequent serious adverse reactions for the combination (≥2%) were bleeding in the gastrointestinal tract and fever. These results were published in the New England Journal of Medicine on 14 May 2020.
Today’s approval follows a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in September 2020. In May 2020, the US Food and Drug Administration approved Tecentriq in combination with Avastin for the treatment of people with unresectable or metastatic HCC who have not received prior systemic therapy. In addition, in October 2020 the China National Medical Products Administration approved the combination for the treatment of people with unresectable HCC who have not received prior systemic therapy. In total, the combination is now approved in 59 countries for people with unresectable HCC. Tecentriq in combination with Avastin was also recently included as
Christian Pulisic has offered a positive update on his fitness at Chelsea, with the United States international claiming to “feel great” as he seeks to rediscover the form that made him an important part of the Blues’ plans last season.
The 22-year-old took a while to find his feet in 2019-20, with the former Borussia Dortmund star needing to adjust his game to meet the demands of life in English football.
Once fully up to speed, only untimely injury issues would hold Pulisic back.
His creativity and keen eye for goal earned him a regular role on the left of Chelsea’s attack, with obvious comparisons drawn with former Blues hero Eden Hazard.
Pulisic is edging his way back towards that level in the current campaign, with a starting berth secured in successive outings against Southampton and Sevilla.
Chelsea have been held in both of those fixtures, as they seek a spark in Premier League and Champions League competition, but their USMNT star feels he is ready to burst into life.
“Fitness-wise I feel great,” Pulisic, who saw a hamstring problem force him out of the 2020 FA Cup final and delay his return to competitive action this term, told Chelsea TV.
“I’m getting back to where I was, I feel strong, I feel like I can play 90 minutes, and I’m happy.”
Pulisic will benefit from the game time he has seen of late, with a testing continental clash with Sevilla giving Lampard and his side plenty of food for thought.
“It was definitely a tough game,” Pulisic added.
“It was one of those where there were not a lot of chances in the game, a really hard-fought match, we did a lot of good defending, and I think we can walk away proud with a point.
“They’re a strong team. They put us to the test, they moved the ball really well and we definitely defended a lot.
“It’s everyone’s job to be behind the ball at times.
“We have to help out defensively. Going away from the game with a clean sheet will give us some confidence. It’s not bad for the guys.
“We have got to find the balance [between defence and attack]. We want to create more chances; I want to help with that. We are going to continue to work to improve as a team.”
Chelsea will face another stern test of their credentials on Saturday when they take in a trip to Manchester United.
LOS ANGELES, Oct. 20, 2020 (GLOBE NEWSWIRE) — RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services today reported it has executed a partnership agreement with Adventist Health to create an outpatient imaging joint venture in Simi Valley, California to initially include three outpatient facilities.
Under the new joint venture, RadNet will contribute two of its Simi Valley imaging Centers, Alamo Advanced Imaging and Simi Valley Advanced Imaging, and Adventist Health will contribute its Aspen Imaging Center. The facilities will together operate MRI, CT, PET/CT, Ultrasound and X-ray modalities.
In addition, RadNet will assume the operational management of Adventist Health’s Nancy Reagan Breast Center, which will perform mammography, breast ultrasound, imaging-guided biopsies and related women’s health services.
Simi Valley, California has a population of approximately 125,000 and is located in the southeast corner of Ventura County, approximately 40 miles from downtown Los Angeles. The joint venture is expected to begin operations no later than January of 2021.
Dr. Howard Berger, Chairman and Chief Executive Officer of RadNet, noted, “We are pleased to announce our new affiliation with Adventist Health, one of the largest health systems on the west coast of the continental United States and Hawaii. Together, both companies have identified an exciting opportunity in the Simi Valley marketplace, a medical community were Adventist Health’s commitment includes the ownership of the leading hospital, an urgent care center, a clinical laboratory, homecare services and various family and specialty physician practices. Aligning with such a high-quality and devoted partner will enhance the service offerings to the referring physician and patient communities of Simi Valley.”
“Adventist Health is pleased to partner with RadNet, the nation’s leading outpatient radiology provider. Our joint venture will advance our imaging capabilities in the region and will provide our medical community with an integrated radiology network offering the full scope of imaging services,” added Jennifer Swenson, President, Adventist Health Simi Valley.
About RadNet, Inc.
RadNet, Inc. is the leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 332 owned and/or operated outpatient imaging centers. RadNet’s core markets include California, Maryland, Delaware, New Jersey, New York, and now Arizona. In addition, RadNet provides radiology information technology solutions, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technicians, RadNet has a total of over 8,600 employees. For more information, visit http://www.radnet.com.
About Adventist Health
Adventist Health is a faith-based, nonprofit integrated health system serving more than 80 communities on the West Coast and Hawaii. Founded on Seventh-day Adventist heritage and values, Adventist Health provides care in hospitals, clinics, home care agencies, hospice agencies, and joint-venture retirement centers in both rural and urban communities. Our compassionate and talented team of 37,000 includes associates, medical staff physicians, allied health professionals, and volunteers driven
When the coronavirus pandemic first hit the UK, thousands of surgical procedures were put on hold. For a surgeon like me who performs operations on deaf children to restore their hearing, this created a significant moral dilemma – I wanted to get back into surgery to provide this vital care, but I didn’t want to inadvertently catch or pass on COVID-19 in the process.
I regularly carry out cochlear implant surgery, a process in which a surgeon embeds an electronic device which stimulates the hearing nerve in the ear. The scientific evidence is clear that this surgery needs to be performed at the earliest opportunity so that these children can benefit from being able to hear at a vital stage in their development.
But performing the surgery as normal would have put both children and surgical teams in danger. We needed to come up with another way of doing things. Our team in Nottingham had to combine creativity and science to develop a novel and safe way to restart cochlear implant surgery in a matter of just a few weeks.
This article is part of Conversation Insights
The Insights team generates long-form journalism derived from interdisciplinary research. The team is working with academics from different backgrounds who have been engaged in projects aimed at tackling societal and scientific challenges.
A grave risk
Soon after the pandemic began, some of the earliest reports, notably those from China and Italy, suggested that healthcare workers were at significantly higher risk of contracting COVID-19 compared to the general public, and that treating ear, nose and throat (ENT) conditions was particularly risky.
I was deeply saddened when I was told that the one of the first healthcare workers in the UK to die of COVID-19 was Amged El-Hawrani, a 55-year-old ENT colleague from the university hospitals of Derby and Burton. El-Hawrani succumbed to this dreadful disease on March 28 in Leicester’s Glenfield hospital. Although I never had the pleasure of meeting him, his passing was a huge shock to us all. And his exposure to the virus during his care for his patients was a stark reminder of the brutality of this disease.
Like other ENT departments across the world, our service at Nottingham University Hospitals NHS Trust initially halted all elective procedures in March when the pandemic hit the UK, so we could concentrate our team’s efforts on the management of our sickest patients, including those conditions requiring emergency admission, and our cancer services.
Although this initial response proved effective, we were aware that we were not meeting the needs of other patients with time-critical, albeit not life-threatening, conditions. These patients included children who are born deaf and need cochlear implant surgery to restore their hearing as quickly as possible to maximise their chances of developing normal speech and language. Delaying cochlear implant